Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Aducanumab is a monoclonal antibody selective for amyloid β (Aβ) aggregates. In June 2021, aducanumab became the first drug underlying the pathophysiology of Alzheimer's disease (AD) approved by the US Food and Drug Administration (FDA), under the accelerated approval pathway. The decision was based on the ability of aducanumab to remove Aβ plaques, without any evidence that the Aβ clearance is correlated with less cognitive or functional decline. This decision has generated a considerable debate in the scientific community, especially because the results from the two Phase 3 trials, EMERGE and ENGAGE, were divergent and, even after the post hoc analysis, the data were insufficient to prove aducanumab efficacy. Moreover, some researchers think that this approval will be an obstacle to the progress and also demonstrated concerns about aducanumab cost and its safety profile. The European Medicines Agency's rejection of aducanumab in December 2021 just brought more controversy over FDA's decision. Now, Biogen is designing the FDA's required confirmatory study, named ENVISION, which should be complete in 2026. Despite the controversy, the aducanumab showed to affect downstream tau pathology, which could open doors for a combination therapy approach for AD (anti-tau and anti-amyloid drug). This review summarizes the clinical development of aducanumab until regulatory agencies' decisions, the available trials data and the controversy over aducanumab approval for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In the EMERGE experiment, when participants with AD were at risk for cognitive deterioration, there was a decrease in the amount of amyloid-beta plaques.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [132]
In the citing paper
“Aducanumab demonstrated inconsistent outcomes in its two main clinical trials, the Phase III EMERGE and ENGAGE research investigations.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [132]
In the citing paper
“In spite of this, the FDA granted expedited approval on the grounds of the EMERGE trial’s documented decrease in amyloid levels [132,185,186,187].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [132]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“According to the amyloid cascade hypothesis, the extracellular accumulation of Aβ aggregates is the leading cause of synapses dysfunction, neuroinflammation, neuronal loss and is also the trigger of tau pathology.(7) Thus, researchers believe that Aβ clearance by aducanumab is a rational mechanism to slow cognitive de…”
BackgroundThe neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329 · cited 1×
“These drugs temporary attenuate symptoms but do not target AD’s two main recognized pathological features: extracellular deposits of amyloid β (Aβ) in plaques and intracellular neurofibrillary tangles (comprised of abnormal tau protein).(3,4) On June 7, 2021, aducanumab (AduhelmTM, Biogen) became the first disease-mod…”
BackgroundAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204 · cited 1×
“Aducanumab: Selective Anti-Aβ Antibody Over the last 25 years, several drugs targeting Aβ have failed to show clinical efficacy in trials, including five anti-Aβ antibodies: bapineuzumab, solanezumab, crenezumab, ponezumab, and gantenerumab.(25,26) Thus, supporters of the amyloid hypothesis placed high hopes on aducan…”
BackgroundThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 4×
“Aducanumab is a monoclonal antibody selective for aggregated forms of Aβ, with demonstrated efficacy in the clearance of brain Aβ plaques.(6) According to the amyloid cascade hypothesis, the extracellular accumulation of Aβ aggregates is the leading cause of synapses dysfunction, neuroinflammation, neuronal loss and i…”
BackgroundMethodInfluentialLane, C. A., Hardy, J., & Schott, J. M. (2018) · European Journal of Neurology · doi:10.1111/ene.13439 · Cited by 2,616 · cited 1×
“These drugs temporary attenuate symptoms but do not target AD’s two main recognized pathological features: extracellular deposits of amyloid β (Aβ) in plaques and intracellular neurofibrillary tangles (comprised of abnormal tau protein).(3,4) On June 7, 2021, aducanumab (AduhelmTM, Biogen) became the first disease-mod…”
Background2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0281-2 · Cited by 947 · cited 2×
“ARIAs are abnormal findings detected in brain magnetic resonance imaging (MRI) and can present as brain edema or sulcal effusions (ARIA-E) and as intracerebral hemorrhage often accompanied by superficial hemosiderin deposits (ARIA-H).(52) Although the mechanism leading to ARIA remains not fully understood, studies sug…”
BackgroundThe Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · cited 1×
“Although the mechanism leading to ARIA remains not fully understood, studies suggest that Aβ clearance causes damage to vessel walls which increases the cerebrovascular permeability and the risk of hemorrhage.(52,53) ARIA has been associated with anti-Aβ antibodies therapies and was reported in the phase 1b trial of a…”
Background
Research works printed but not linked: 6
- World Health Organization. Global action plan on the public health response to dementia 2017–2025. Geneva:World Heal Organ; 2017: 27. Available from: http://www.who.int/mental_health/neurology/dementia/action_plan_2017_2025/en/. Accessed May 14, 2022.
- Eisai. Japan’s first committee on new drugs of the pharmaceutical affairs and food sanitation council seeks additional data; aducanumab remains under review. Eisai Global; 2021. Available from: https://www.eisai.com/news/2021/news2021101.html. Accessed April 9, 2022.
- Bussiere, 2013, Neurodegener Dis, 11, 2576
- Biogen. Update on regulatory review of aducanumab in the European Union. Biogen. Available from: https://investors.biogen.com/news-releases/news-release-details/update-regulatory-submission-aducanumab-european-union.; 2021. Accessed April 9, 2022.
- Institute for Clinical and Economic Review. ICER issues statement on the FDA’s approval of aducanumab for Alzheimer’s disease. ICER; 2021. Available from: https://icer.org/news-insights/press-releases/icer-issues-statement-on-The-fdas-approval-of-aducanumab-for-alzheimers-disease/. Accessed November 11, 2021.
- Association AF. Aduhelm lowers tau; registry to track real-world performance | ALZFORUM. Alzforum; 2021. Available from: https://www.alzforum.org/news/conference-coverage/aduhelm-lowers-tau-registry-track-real-world-performance. Accessed February 1, 2022.
Cited by
Singh, B., Day, C. M., Abdella, S., & Garg, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.047 · Cited by 228
Safiri, S., Ghaffari Jolfayi, A., Fazlollahi, A., Morsali, S., Sarkesh, A., Daei Sorkhabi, A., Golabi, B., Aletaha, R., Motlagh Asghari, K., Hamidi, S., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1474043 · Cited by 200
Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications
Doran, S. J., & Sawyer, R. P. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1326784 · Cited by 147
“The incidence of ARIA is variable with the different anti-amyloid therapeutics with ARIA-E incidence ranging from 0.9–40.6% (Table 1; Carlson et al., 2016; Avgerinos et al., 2021; Barakos et al., 2022; Jeong et al., 2022; Salloway et al., 2022; Vaz et al., 2022).”
BackgroundInfluentialTang, B., Wang, Y., & Ren, J. (2023) · Ibrain · doi:10.1002/ibra.12098 · Cited by 137
“In December 2021, the European Medicines Agency denied the approval of aducanumab for AD treatment, resulting in more skepticism as to whether the drug is effective and safe.(38) Also, aducanumab is expensive: about $28,000 per person per year, making it unaffordable for the average family.”
BackgroundFišar, Z. (2022) · Biomolecules · doi:10.3390/biom12111676 · Cited by 120
“The mechanism of action of aducanumab (significant reduction of Aβ in the cerebral cortex) supports the amyloid hypothesis of AD [349]; however, its effect on the progression of cognitive decline or dementia in AD cannot be considered proven [319,350].”
BackgroundAducanumab for the treatment of Alzheimer’s disease: A systematic review
Rahman, A., Hossen, M. A., Chowdhury, M. F. I., Bari, S., Tamanna, N., Sultana, S. S., Haque, S. N., Al Masud, A., & Saif‐Ur‐Rahman, K. M. (2023) · Psychogeriatrics · doi:10.1111/psyg.12944 · Cited by 104
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102
Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813900 · Cited by 94
“However, in March 2019, Eisai and Biogen announced the termination of all ongoing aducanumab trials due to the failure of interim analysis [61,62].”
BackgroundDighe, S., Jog, S., Momin, M. M., Sawarkar, S. P., & Omri, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010058 · Cited by 105
“A significant breakthrough in AD research occurred with the recent FDA approval (2021) of the first disease-modifying monoclonal antibody, aducanumab (Aduhelm ® ) [38], which targets A β plaques, including both insoluble fibrils and oligomers [39].”
BackgroundLoeffler, D. A. (2023) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-230025 · Cited by 79
“Conflicting results in two phase III trials were reported in 2019 for the monoclonal antibody Aducanumab [33, 34].”
ResultKhedraoui, M., Nour, H., Yamari, I., Abchır, O., Errougui, A., & Chtita, S. (2023) · Chemical Physics Impact · doi:10.1016/j.chphi.2023.100361 · Cited by 67
Review on anti-alzheimer drug development: approaches, challenges and perspectives
Abdallah, A. E. (2024) · RSC Advances · doi:10.1039/d3ra08333k · Cited by 72
Alkhalifa, A. E., Mokhlf, A. A., Ali, H., Al-Ghraiybah, N. F., & Syropoulou, V. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15090437 · Cited by 77
“The EMA’s more conservative approach emphasizes that without clear functional improvement, risks such as ARIAs may outweigh potential benefit at a population level [62].”
Recent Advances in Drug Development for Alzheimer’s Disease: A Comprehensive Review
Xing, H., Yue, S., Qin, R., Du, X., Wu, Y., Zhangsun, D., & Luo, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083905 · Cited by 71
“However, the FDA mandated a post approval confirmatory trial, ENVISION, to verify the clinical benefits, with results expected in 2026 [72].”
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56
“Every four weeks, an intravenous (IV) dose is administered [132,133].”
BackgroundCurrent landscape of innovative drug development and regulatory support in China
Tan, R., Hua, H., Zhou, S., Yang, Z., Yang, C., Huang, G., Zeng, J., & Zhao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02267-y · Cited by 51
Lott, S. A., Streel, E., Bachman, S. L., Bode, K., Dyer, J., Fitzer-Attas, C., Goldsack, J. C., Hake, A., Jannati, A., Fuertes, R. S., et al. (2024) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2024.103 · Cited by 48
“The recent regulatory approval of some therapeutic agents targeting AD pathophysiology highlights the complexity of dementia management, as new treatment opportunities emerge alongside ongoing challenges in dementia research, clinical management, and holistic patient care (7).”
BackgroundUnveiling the impact of aging on BBB and Alzheimer's disease: Factors and therapeutic implications
Nelson, V. K., Jha, N. K., Nuli, M. V., Gupta, S. K., Kanna, S., Gahtani, R. M., Hani, U., Singh, A. K., Abomughaid, M. M., Abomughayedh, A. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102224 · Cited by 48
Lorenzo, D. D. (2024) · ChemMedChem · doi:10.1002/cmdc.202400180 · Cited by 49
Yarbro, J. M., Shrestha, H. K., Wang, Z., Zhang, X., Zaman, M., Chu, M., Wang, X., Yu, G., & Peng, J. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00874-5 · Cited by 46
“However, their efficacy is still limited, and their broader impact on disease progression remains uncertain [5–7], highlighting the gap in our understanding of AD pathophysiology beyond amyloid clearance.”
New Possibilities in the Therapeutic Approach to Alzheimer’s Disease
Doroszkiewicz, J., & Mroczko, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168902 · Cited by 50
“It is a new-generation monoclonal antibody that is selective to Aβ aggregates, which makes it the first drug rooted in the pathophysiology of AD [47].”
BackgroundImplications of Microorganisms in Alzheimer’s Disease
Yadav, P., Lee, Y., Panday, H., Kant, S., Bajwa, N., Parashar, R., Jha, S. K., Jha, N. K., Nand, P., Lee, S., et al. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44100314 · Cited by 40
“However, increased amyloid-related imaging abnormality (ARIA) was observed depending on the dose and the APOE4 genotype (Clinical Trials: NCT01397539, NCT01677572) [216].”
BackgroundTondo, G., Marchi, F. D., Bonardi, F., Menegon, F., Verrini, G., Aprile, D., Anselmi, M., Mazzini, L., & Comi, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113098 · Cited by 46
“The approval of aducanumab triggered a sharp debate on the opportunity to approve a drug showing only minimal clinical benefit in a post hoc analysis of a single study [142].”
BackgroundDetection of protein oligomers with nanopores
Horne, R. I., Sandler, S. E., Vendruscolo, M., & Keyser, U. F. (2025) · Nature Reviews Chemistry · doi:10.1038/s41570-025-00694-7 · Cited by 42
“1d), do not correlate well with patient outcome 18,26–29 .”
Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021
Martins, A. C., Oshiro, M. Y., Alberício, F., de la Torre, B. G., Pereira, G. J. V., & Gonzaga, R. V. (2022) · Biomedicines · doi:10.3390/biomedicines10092325 · Cited by 43
“In this regard, the European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency (PMDA) withdrew marketing authorization for this drug in 2021 [26].”
BackgroundComprehensive Review of Nutraceuticals against Cognitive Decline Associated with Alzheimer’s Disease
Reza-Zaldívar, E. E., & Jacobo‐Velázquez, D. A. (2023) · ACS Omega · doi:10.1021/acsomega.3c04855 · Cited by 47
Zhao, T., Shi, Q., Zhang, X., & Zhang, T. (2024) · Journal of Retailing and Consumer Services · doi:10.1016/j.jretconser.2024.103886 · Cited by 38
Chin, E., Jaqua, E. E., Safaeipour, M., & Ladue, T. (2022) · Cureus · doi:10.7759/cureus.31065 · Cited by 47
“Despite this, results were deemed promising, and aducanumab was moved to clinical trials in 2011 [37].”
BackgroundMethodResultInfluentialAilioaie, L. M., Ailioaie, C., & Litscher, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030916 · Cited by 44
Dominguez-Gortaire, J. A., Ruiz, A., Porto-Pazos, A. B., Rodríguez, S., & Cedrón, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031004 · Cited by 36
Sharma, A., & Bharate, S. B. (2023) · ACS Omega · doi:10.1021/acsomega.2c07993 · Cited by 32
Potential implications of polyphenolic compounds in neurodegenerative diseases
Shi, R., Gao, D., Стойка, Р. С., Liu, K., Attila Gabor, S. I. K., & Jin, M. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2155106 · Cited by 36
Patel, R. S., Lui, A., Hudson, C., Moss, L. D., Sparks, R. P., Hill, S. E., Shi, Y., Cai, J., Blair, L. J., Bickford, P. C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-022-27126-6 · Cited by 35
Khan, M. S., Qureshi, N., Khan, R., Son, Y., & Maqbool, T. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1578138 · Cited by 38
Martin, S. P., & Leeman-Markowski, B. A. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2023.1287545 · Cited by 36
“Results indicated that aducanumab was associated with dose-dependent amyloid related imaging abnormalities (ARIA), with cerebral edema and increased risk of intracerebral hemorrhage, particularly in ApoE-ɛ 4 carriers (276).”
BackgroundDebnath, I., Ghosh, S., Jha, S. K., Bhunia, S., Nayak, A., Basak, S., Nandi, S., & Bhattacharjee, S. (2025) · BIO Integration · doi:10.15212/bioi-2025-0073 · Cited by 35
Exploring Alzheimer's disease treatment: Established therapies and novel strategies for future care
Soni, U., Singh, K., Jain, D., & Pujari, R. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177520 · Cited by 33
Sugandhi, V. V., Gadhave, D. G., Ugale, A. R., Kulkarni, N. N., Nangare, S., Patil, H. P., Rath, S., Saxena, R., Lavate, A., Patel, A. T., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102775 · Cited by 35
Immunotherapy for Parkinson’s Disease and Alzheimer’s Disease: A Promising Disease-Modifying Therapy
Mahboob, A., Ali, H., Naimi, A. J. A., Yousef, M., Rob, M., Al-Muhannadi, N. A., Senevirathne, D. K. L., & Châari, A. (2024) · Cells · doi:10.3390/cells13181527 · Cited by 30
Sonwani, A., Pathak, A., & Jain, K. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105855 · Cited by 27
Meghdadi, A. H., Salat, D. H., Hamilton, J. M., Hong, Y., Boeve, B. F., Louis, E. K. S., Verma, A. K., & Berka, C. (2024) · PLoS ONE · doi:10.1371/journal.pone.0308137 · Cited by 32
Evidence of disturbed insulin signaling in animal models of Alzheimer’s disease
Alves, S. S., Servilha‐Menezes, G., Rossi, L., da Silva-Júnior, R. M. P., & Garcia‐Cairasco, N. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105326 · Cited by 27
Mishra, K. A., & Sethi, K. K. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400748 · Cited by 23
Lithium Provides Broad Therapeutic Benefits in an Alzheimer’s Disease Mouse Model
Wiseman, A. L., Briggs, C. A., Peritt, A., Kapecki, N., Peterson, D. A., Shim, S. S., & Stutzmann, G. E. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220758 · Cited by 23
Research Progress on the Pathogenesis, Diagnosis, and Drug Therapy of Alzheimer’s Disease
Yang, Y., & Qiu, L. (2024) · Brain Sciences · doi:10.3390/brainsci14060590 · Cited by 23
“Aducanumab can originally inhibit A β by impeding the formation of A β oligomer on the surface of primary fibers [160].”
BackgroundWang, X., Xie, Y., Fan, X., Wu, X., Wang, D., & Li, Z. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01489-6 · Cited by 28
“Recently, several monoclonal antibody drugs directed against Aβ have shown positive outcomes in AD treatment [3–5], indicating that reducing the toxic Aβ load in the brain is beneficial in AD treatment, particularly to improve cognitive function.”
BackgroundJin, J., Zhang, H., Lu, Q., Tian, L., Yao, S., Lai, F., Liang, Y., Liu, C., Lu, Y., Tian, S., et al. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00303 · Cited by 23
The Role of Dietary Antioxidants and Their Potential Mechanisms in Alzheimer’s Disease Treatment
Knight, E., Geetha, T., Broderick, T. L., & Babu, J. R. (2023) · Metabolites · doi:10.3390/metabo13030438 · Cited by 21
“Despite data indicating that aducanumab reduces Aβ plaques, current data on the impact of aducanumab on cognitive function is inconclusive, and the drug is associated with cerebral edema and intracerebral hemorrhages [32,33].”
BackgroundInfluentialTargeting calcium signaling in Alzheimer’s disease: challenges and promising therapeutic avenues
Song, L., Tang, Y. P., & Law, B. Y. K. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.380898 · Cited by 21
Symptoms and conventional treatments of Alzheimer's disease
Chorawala, M. R., Shah, A. C., Pandya, A. J., Kothari, N. R., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00009-1 · Cited by 21
Schreiner, T. G., Menéndez‐González, M., & Popescu, B. O. (2022) · Biomedicines · doi:10.3390/biomedicines10071509 · Cited by 19
“This fast-forward approval has generated at the same time a fierce debate in the research community, as its impact on cognition and the functional decline was not completely demonstrated [75].”
BackgroundFunctional aspects of the brain lymphatic drainage system in aging and neurodegenerative diseases
Chen, Y., He, X., Cai, J., & Li, Q. (2024) · Journal of Biomedical Research · doi:10.7555/jbr.37.20230264 · Cited by 19
Experimental approaches for altering the expression of Abeta‐degrading enzymes
Loeffler, D. A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15762 · Cited by 20
“Aducanumab was approved by the United States Food and Drug Administration (FDA) in June 2021 via an accelerated approval mechanism despite controversy relating to differing results in its two phase 3 trials (Budd Haeberlein et al., 2022; Vaz et al., 2022).”
BackgroundBi, Z., Wang, L., & Wang, W. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/161734 · Cited by 21
Qi, X., Nizamutdinov, D., Yi, S. S., Wu, E., & Huang, J. H. (2024) · Biomedicines · doi:10.3390/biomedicines12112636 · Cited by 19
Gehlot, P., Pathak, R., Kumar, S., Choudhary, N. K., & Vyas, V. K. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117925 · Cited by 20
Amyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer’s Treatment
Fatima, R., Khan, Y., Maqbool, M., Ramalingam, P. S., Khan, M. G., Bisht, A. S., & Hussain, M. S. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037362037250205143911 · Cited by 20
From Small Peptides to Large Proteins against Alzheimer’sDisease
Picone, P., Sanfilippo, T., Vasto, S., Baldassano, S., Guggino, R., Nuzzo, D., Bulone, D., Biagio, P. L. S., Muscolino, E., Monastero, R., et al. (2022) · Biomolecules · doi:10.3390/biom12101344 · Cited by 18
Exogenous Oxytocin Administration Restores Memory in Female APP/PS1 Mice
Koulousakis, P., Willems, E., Schepers, M., Rombaut, B., Prickaerts, J., Vanmierlo, T., & van den Hove, D. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230657 · Cited by 19
Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
Wicker, A., Shriram, J., Decourt, B., & Sabbagh, M. N. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00664-z · Cited by 18
Aleksandrova, Y. R., Munkuev, A. A., Mozhaitsev, E. S., Суслов, Е. В., Tsypyshev, D. O., Chaprov, K., Бегунов, Р. С., Volcho, K. P., Salakhutdinov, N. F., & Неганова, М. Е. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119743 · Cited by 15
Emerging paradigms in Alzheimer's therapy
Agnes Preethy, H., Rajendran, K., Sukumar, A. J., & Krishnan, U. M. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176872 · Cited by 18
More failure with solanezumab – this time in preclinical Alzheimer’s disease
Doggrell, S. A. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2325551 · Cited by 12
“However, this was not enough evidence for the approval agencies in Europe and Japan to approve aducanumab (reviewed in [18]).”
BackgroundSchreiner, T. G., Croitoru, C. G., Hodorog, D. N., & Cuciureanu, D. I. (2024) · Biomedicines · doi:10.3390/biomedicines12051096 · Cited by 15
“US trial, proposed to enroll roughly 6000 persons, was designed to produce data on long-term and validate clinical outcomes [78].”
BackgroundAlzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates
Hroudová, J., & Fišar, Z. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111069 · Cited by 13
The future of complement therapeutics
Kolev, M. V., Rao, K. N., Yeh, M. W., Parikh, A., & Deschatelets, P. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00161 · Cited by 15
Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease
Sha, S., Ren, L., Xing, X., Guo, W., Wang, Y., Li, Y., Cao, Y., & Qu, L. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00846 · Cited by 19
Recent Progress in the Treatment Strategies for Alzheimer’s Disease
Kumar, V., & Roy, K. (2023) · Neuromethods · doi:10.1007/978-1-0716-3311-3_1 · Cited by 13
The aquaporin-4 water channel and updates on its potential as a drug target for Alzheimer’s disease
Silverglate, B., Gao, X., Lee, H., Maliha, P., & Grossberg, G. T. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2240017 · Cited by 12
Evolution of lipid nanoparticles as charioteers of Alzheimer's disease therapeutics
Chakraborty, B., Patel, G., Padhan, B., Das, J., & Patel, M. (2024) · Applied Materials Today · doi:10.1016/j.apmt.2024.102442 · Cited by 18
Kurowska, E., Ruciński, J., Myślińska, D., Grembecka, B., Wrona, D., & Majkutewicz, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415449 · Cited by 13
“Currently, there are only six drugs for the treatment of AD that have been approved by the US Food and Drug Administration (FDA) [15].”
BackgroundGrover, P., Rohilla, S., Bhardwaj, M., Mehta, L., & Malhotra, A. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230406084315 · Cited by 16
Hu, H., Zhao, Y., Mao, J., He, J., Zhang, Y., Ye, H., & Yang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1561020 · Cited by 14
“Its high cost and elevated ARIA event rate have sparked debates on whether its bene fi ts outweigh the risks and fi nancial burdens on the healthcare system (Vaz et al., 2022).”
Aguzzoli, E., Walbaum, M., Knapp, M. R. J., Castro‐Aldrete, L., Chadha, A. S., & Cyhlarova, E. (2025) · Archives of Public Health · doi:10.1186/s13690-025-01626-z · Cited by 11
Effects of Probiotics on Colitis-Induced Exacerbation of Alzheimer’s Disease in AppNL-G-F Mice
Sahu, B., Johnson, L. M., Sohrabi, M., Usatii, A. A., Craig, R. M. J., Kaelberer, J. B., Chandrasekaran, S. P., Kaur, H., Nookala, S., & Combs, C. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411551 · Cited by 10
“Even recent results from anti-Aβ immunotherapy are not entirely clear, suggesting that additional data are required to confirm its efficacy [11,12,14].”
BackgroundAtypical instantaneous spatio-temporal patterns of neural dynamics in Alzheimer’s disease
Nobukawa, S., Ikeda, T., Kikuchi, M., & Takahashi, T. (2024) · Scientific Reports · doi:10.1038/s41598-023-50265-3 · Cited by 14
“Although effective treatments for AD are controversial, recent studies have shown that the early diagnosis of AD and early intervention significantly delay disease evolution 48 .”
BackgroundBotan, M. V. G., da Silva, J. B., & Bruschi, M. L. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02974-9 · Cited by 11
“A major reported disadvantage is the high incidence of brain swelling and bleeding [23].”
Sharma, M. R., Thakur, S., Jadhav, H. R., & Bharate, S. B. (2023) · ChemistrySelect · doi:10.1002/slct.202301879 · Cited by 10
Махаева, Г. Ф., Ковалева, Н. В., Рудакова, Е. В., Boltneva, N. P., Lushchekina, S. V., Astakhova, T. Y., Timokhina, E. N., Serebryakova, O. G., Shchepochkin, A. V., Averkov, M. A., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1219980 · Cited by 11
Current trends and updates in the treatment of Alzheimer's disease
Parikh, N. H., Parikh, P. K., Rao, H. J., Shah, K., Dave, B. P., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00014-5 · Cited by 9
Yoon, E., Ahn, J. W., Kim, H.-S., Choi, Y., Jeong, J., Joo, S. S., & Park, D. (2023) · Nutrients · doi:10.3390/nu15153389 · Cited by 11
Integrating NLP and LLMs to discover biomarkers and mechanisms in Alzheimer's disease
Song, J., Huang, J., & Liu, R. (2025) · SLAS TECHNOLOGY · doi:10.1016/j.slast.2025.100257 · Cited by 11
Soria-Tobar, L., Román-Valero, L., Sebastián‐Serrano, Á., Aivar, P., Alvarez‐Castelao, B., & Díaz-Hernández, M. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01600-x · Cited by 8
“Nonetheless, these drugs have very limited applicability (only in middle cognitive impairment (MCI) patients), have several side effects, and their substantial cost burden raises questions about their cost-effectiveness [17, 18].”
BackgroundGarni, H. A. A., Halawany, A. M. E., Koshak, A. E., Malebari, A. M., Alzain, A. A., Mohamed, G. A., Ibrahim, S. R. M., Sayed, N. S. E., & Abdallah, H. M. (2024) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2024.2352725 · Cited by 7
“Dementia usually affects older adults and accounts for around half to over half of dementia cases among people 65 years and older [3].”
BackgroundPatwekar, M., Patwekar, F., Khan, S. M., Sharma, R., & Kumar, D. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266295495240415114919 · Cited by 9
Prejanò, M., Romeo, I., Hernández‐Ayala, L. F., Guzmán‐López, E. G., Alcaro, S., Galano, A., & Marino, T. (2024) · ChemPhysChem · doi:10.1002/cphc.202400653 · Cited by 6
Mushtaq, M., Khan, M. A., Hussain, Z., Ayouni, S., Maddeh, M., & Alhayan, F. (2025) · Cognitive Computation · doi:10.1007/s12559-025-10505-2 · Cited by 6
“Aducanumab is the first medication for Alzheimer’s disease to receive licensure since 2003 [12].”
A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system
Huang, J., Long, X., & Chen, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1522058 · Cited by 8
“The safety signals identi fi ed through our analysis, particularly ARIA-related events, warrant careful consideration but should be viewed within the context of the drug ’ s potential therapeutic bene fi ts (Vaz et al., 2022).”
Natural IgG antibodies to β amyloid are decreased in patients with Parkinson’s disease
Paganelli, R., Paganelli, A., Pawelec, G., & Iorio, A. D. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00336-w · Cited by 6
Smirnova, A. A., & Живолупов, С. А. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-099 · Cited by 6
Burroughs, A. W., & Krain, L. (2023) · The AMA Journal of Ethic · doi:10.1001/amajethics.2023.777 · Cited by 5
Neurodegeneration emerges at a cellular tipping point between aggregate accumulation and removalPreprint
Cotton, M. W., Venkatesan, S., Beckwith, J. S., Böken, D., Xu, C. K., Fertan, E., Breiter, J. C., Berkowicz, L. E., Salazar, L. S., Schulze, A. T. V., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.08.674880 · Cited by 7
“For example, antibody based therapeutics, such as the anti-amyloid antibodies licensed for AD [44, 45], aim to increase the removal rate of aggregates, whereas aggregation inhibitors (Fig.”
Challenges and opportunities in nanotherapeutics targeted for central nervous system disorders
Yong, J. M., Hakobyan, K., Mahmud, S. A. Z., Johnson, D., Lee, J., Diwan, A. D., Gu, Z., Moalem‐Taylor, G., & Mao, G. (2025) · Nanoscale · doi:10.1039/d5nr02463c · Cited by 5
Seo, J., Kim, J., Ko, Y., Lee, B., Hur, K., Jung, Y. H., Park, H., Lee, S., & Jang, C. (2025) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.110 · Cited by 5
Jang, B.-G., Choi, B., Kim, S., Lee, D.-S., Lee, J., Koh, Y. H., Jo, S. A., Kim, J., Kang, T., & Kim, M.-J. (2022) · Cells · doi:10.3390/cells11162585 · Cited by 5
“However, they were not successful as candidate components had critical side effects, such as cerebral microhemorrhages following the passive immunization with AN-1792 from Elan Pharmaceuticals, except Aducanumab, the first anti-Aβ therapy approved by the Food and Drug Administration (FDA) in 2021 [6,7].”
BackgroundInfluentialYi, J. H., Cho, E., Lee, S., Kwon, K. J., Lee, S., Lee, J., Lee, C., Shin, C. Y., Kim, D. H., & Shim, S. H. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115792 · Cited by 8
Sharma, A., Rudrawar, S., Sharma, A., Bharate, S. B., & Jadhav, H. R. (2024) · RSC Advances · doi:10.1039/d4ra04315d · Cited by 5
“20,21 Targeting BACE 1 is crucial in the development of drugs for Alzheimer's disease.”
BackgroundLipid nanocarriers encapsulating herbal drugs for brain diseases therapy
Gad, S., El-Gogary, R. I., Geneidi, A. S., & Hathout, R. M. (2023) · Archives of Pharmaceutical Sciences Ain Shams University · doi:10.21608/aps.2023.202432.1115 · Cited by 7
“Interestingly, the FDA approved monoclonal antibody, Aducanumab, as the first disease-modifying therapy for AD which has appeared to prevent AD progression in early stages by reducing amyloid protein deposition in the brain [23, 24] .”
BackgroundAlzheimer’s Disease: Evolving Therapeutics, Scientific Progress, and Key Challenges
Sai Yasasvi, K., Goswami, A. K., Prasad, M. R., Chauhan, V. S., & Yadav, N. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02468 · Cited by 6
Srivastava, A., Renna, H. A., Johnson, M., Sheehan, K., Ahmed, S., Palaia, T. A., Pinkhasov, A., Gomolin, I. H., Wısnıewskı, T., Leon, J. D., et al. (2024) · Life · doi:10.3390/life14101241 · Cited by 8
“Further investigation to determine possible mechanisms of neuroprotection with nilotinib using neurons derived from AD subjects is warranted as we await the results of clinical trials.”
Background
Metadata
- Authors
- Vaz, M., Silva, V., Monteiro, C., & Silvestre, S.
- Affiliations
- University of Beira Interior (PT)
- Corresponding author
- Vaz, Miguel
- Venue
- Clinical Interventions in Aging
- Publisher
- Informa UK Limited
- Published
- 2022-05
- Volume
- Volume 17
- Pages
- 797-810
- ISSN
- 1176-9092 (ISSN-L)
- 1178-1998
- PMC
- PMC9124475
- OpenAlex
- W4280613528
- Cited by
- 183
- References
- 48
- Citations by year
- 2026: 26 · 2025: 42 · 2024: 58 · 2023: 41 · 2022: 16
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Interventions in Aging (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Programa Operacional Regional do Centro (CENTRO-01-0145-FEDER-000013)
- Fundação para a Ciência e a Tecnologia (UID/Multi/00709, UID/Multi/00709/2019, 01-0145, COMPETE, POCI-01-0145, POCI-01-0145-FEDER-, COMPETE_2020, 00709/2019, POCI-01-, POCI-01-0145-FEDER- 007491, CENTRO-01-0145-FEDER-000013, 007491, 00709)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- aducanumab, Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, accelerated approval, tau pathology, combination therapy, drug safety, drug costs, regulatory decision-making
- MeSH terms
- Alzheimer Disease, Humans, United States, United States Food and Drug Administration, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

